These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35129014)

  • 1. Safety considerations with the current treatments for peripheral T-cell lymphoma.
    Sethi T; Montanari F; Foss F
    Expert Opin Drug Saf; 2022 May; 21(5):653-660. PubMed ID: 35129014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
    Armitage JO; Hsi ED; Foss FM
    Clin Adv Hematol Oncol; 2010 Dec; 8(12 Suppl 22):1-15. PubMed ID: 21491667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment algorithms for mature T-cell and natural killer-cell neoplasms.
    Tse E; Kwong YL
    Future Oncol; 2011 Sep; 7(9):1101-12. PubMed ID: 21919697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Peripheral T-cell lymphoma: diagnosis and treatment].
    Reimer P; Hentrich M
    Dtsch Med Wochenschr; 2006 Mar; 131(13):685-90. PubMed ID: 16555177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Barbarotta L; Hurley K
    J Adv Pract Oncol; 2015; 6(1):22-36. PubMed ID: 26413372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
    Ma H; O'Connor OA; Marchi E
    Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
    Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
    Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
    Nizamuddin I; Galvez C; Pro B
    Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
    Alrifai D; Pettengell R
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation.
    Zain J
    Cancer Treat Res; 2019; 176():269-287. PubMed ID: 30596223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.